Last reviewed · How we verify
NCT06933238: FZTFJD
Efficacy of Fuzheng Tongfu Jiedu Prescription for Treating Gastrointestinal Dysfunction Associated With Sepsis
Phase 1, PHASE2 trial testing Fuzheng Tongfu Jiedu prescription (FZTFJD) in Sepsis Abdominal in 70 participants. Not yet recruiting.
30 June 2026
Quick facts
| Lead sponsor | Dongzhimen Hospital, Beijing |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 70 |
| Start date | 25 April 2025 |
| Primary completion | 30 June 2026 |
| Estimated completion | 30 June 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Fuzheng Tongfu Jiedu prescription (FZTFJD) — full drug profile →
- Placebo
Conditions studied
- Sepsis Abdominal — all drugs for Sepsis Abdominal →
- Gastrointestinal Dysfunction — all drugs for Gastrointestinal Dysfunction →
- Traditional Chinese Medicine — all drugs for Traditional Chinese Medicine →
Sponsor
Dongzhimen Hospital, Beijing
Who can join
Adults 50 to 90, any sex, with Sepsis Abdominal or Gastrointestinal Dysfunction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a single-center, randomized, double-blind, placebo-controlled trial.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06933238
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sepsis Abdominal
Currently open trials in the same condition.
- NCT07442552 — Perioperative Sepsis. An Epigenetic Perspective · recruiting
- NCT07239713 — Clinical Effects of Ringers Lactate Versus Sterofundin/ Plasmalyte Solution in Patients With Sepsis · NA · recruiting
- NCT06614088 — Serum Calprotectin in Surgical Septic Patients · recruiting
Other Dongzhimen Hospital, Beijing trials
Trials by the same sponsor.
- NCT07271732 — Songling Xuemaikang Capsules for Cerebral Small Vessel Disease · NA · not yet recruiting
- NCT07342075 — Registry Study of Cerebral Small Vessel Disease · recruiting
- NCT07163702 — Efficacy and Safety of Xinglou Chengqi Granule for Acute Ischemic Stroke · Phase 2 · not yet recruiting
- NCT06857487 — Qingre Huatan Formula for the Prevention of Early Neurological Deterioration in Acute Ischemic Stroke · Phase 1, PHASE2 · recruiting
- NCT06686355 — The Treatment of Sepsis Induced Myocardial Dysfunction With Yiqilishui Formula · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06933238 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dongzhimen Hospital, Beijing
- Last refreshed: 18 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06933238.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing